mardi 31 janvier 2017

Onco Actu du 31 janvier 2017

1. Biologie

Is there a reproducibility “crisis” in biomedical research? (2017 edition) [Respectful Insolence]

3.1 Tabac

£760 million annual bill from smoking ‘adding to social care crisis’ [Cancer Research UK]

Smokers face tighter rules as Japanese capital eyes smoke-free Olympics [Reuters]

3.3 Prévention - Vaccins

HPV vaccine now funded for boys – Expert Q&A [Science Media Center]

4. Dépistage, diagnostic et pronostic

Breath test shows potential for detecting cancer [NHS Choices]

4.10 Dép., diag. & prono. - Poumon

Lung Cancer Screening Program Finds A Lot That's Not Cancer [NPR]

5. Traitements

Ovarian Chemo Shield? [Harvard Medical School]

Less-Frequent Zoledronic Acid Treatment Effective at Preventing Bone Metastasis Complications [NCI]

5.10 Traitements - Essais

Consider drug efficacy before first-in-human trials [Nature]

5.2 Pharma

Incyte grabs control of a cancer drug from Calithera’s pipeline for $53M up front [EndPoints]

5.2.1 Pharma - Partenariats

Exelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan [Exelixis]

5.4 Traitements - Economie

1,100% generic cancer drug price increases fly below UK radar [Pharmafile]

6. Lutte contre les cancers

European experts highlight the potential of xenografts in personalized oncology [EurekAlert!]

6.10.1 Politiques (USA)

MIT responds to Trump’s executive order on travel [MIT News]

‘Two Out, One In’: Trump Signs Executive Order to Repeal Regulations [RAPS]

Trump order on regulations could create hurdles for FDA, Cures Act [STAT]

ASCO Statement on the U.S. Presidential Executive Order on Entry Into the United States [ASCO]

6.5 Médecines alternatives

“Detox”: Ritual purification masquerading as medicine and wellness [Science-Based Medicine]

6.6 Publications

Study of child with rare cancer retracted due to lack of parental consent [Retraction Watch]

6.7.3 DMP

Copy fees limit patient access to medical records, doctors argue [Reuters]